Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Non-Current Deffered Revenue (2016 - 2024)

Historic Non-Current Deffered Revenue for Ligand Pharmaceuticals (LGNYZ) over the last 13 years, with Q4 2024 value amounting to $2.2 million.

  • Ligand Pharmaceuticals' Non-Current Deffered Revenue rose 5554.02% to $2.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.2 million, marking a year-over-year increase of 5554.02%. This contributed to the annual value of $2.2 million for FY2024, which is 5554.02% up from last year.
  • According to the latest figures from Q4 2024, Ligand Pharmaceuticals' Non-Current Deffered Revenue is $2.2 million, which was up 5554.02% from $2.5 million recorded in Q3 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Non-Current Deffered Revenue peaked at $9.3 million during Q4 2021, and registered a low of $44000.0 during Q4 2022.
  • Moreover, its 4-year median value for Non-Current Deffered Revenue was $2.7 million (2024), whereas its average is $3.8 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Non-Current Deffered Revenue tumbled by 9952.54% in 2022 and then skyrocketed by 318181.82% in 2023.
  • Ligand Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $9.3 million in 2021, then crashed by 99.53% to $44000.0 in 2022, then skyrocketed by 3181.82% to $1.4 million in 2023, then surged by 55.54% to $2.2 million in 2024.
  • Its Non-Current Deffered Revenue was $2.2 million in Q4 2024, compared to $2.5 million in Q3 2024 and $2.7 million in Q2 2024.